It really doesn’t make sense that they waited. DI’s supposed reasoning, if that’s what he said, is BS.
Some have speculated it’s because the FDA may have remained silent. That too seems like a bogus reason, because silence means no initial rejection.
Finally, another argument is that NWBO was awaiting a guideline finalization before changing the endpoints. I’m not an expert on why this would have helped, since endpoints can be changed before endpoint guidelines are finalized.
It’s still weird to me why they’d wait in the U.S. since they didn’t wait overseas?? It’s not like they were going to leave it as different endpoints in different locals.
I’m still scratching my head.
It’s concerning they didn’t want the price to rise a year or so ago (if true), but maybe I’m missing something.
Market Data 
Markets 
AI
